[SCHEDULE 13G] PMV Pharmaceuticals, Inc. Passive Investment Disclosure (>5%)
Samsara reports 9.99% stake in PMV Pharma
Samsara BioCapital affiliates and Srinivas Akkaraju report 9.99% beneficial ownership of PMV Pharmaceuticals via shares and warrants subject to a 9.99% blocker.
PMV Pharmaceuticals, Inc. (PMVP) is reported to have a significant shareholder group led by Samsara BioCapital entities and Srinivas Akkaraju. The reporting persons disclose beneficial ownership of 7,577,467 shares of common stock, representing 9.99% of PMV’s outstanding common stock.
The holdings include, for each of Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P., 3,620,000 common shares, Pre-Funded Warrants exercisable for up to 3,400,000 shares, and Common Warrants exercisable for up to 7,020,000 shares. All percentages are calculated using 53,458,058 shares outstanding as of August 14, 2026 plus 22,055,000 shares issued in PMV’s September 2, 2026 equity offering and Warrants exercisable within 60 days.
Each Warrant contains a Beneficial Ownership Blocker that prevents exercises which would cause the holder and its affiliates to own more than 9.99% of PMV’s common stock, limiting further Warrant exercise above 7,577,467 shares currently attributed to the reporting group.
Positive
None.
Negative
None.
Key Figures
Shares beneficially owned by reporting persons:7,577,467 sharesBeneficial ownership percentage (Dr. Akkaraju):9.99%Common shares held by each Samsara fund:3,620,000 shares+5 more
8 metrics
Shares beneficially owned by reporting persons7,577,467 sharesBeneficial ownership of PMV Pharmaceuticals common stock attributed to Srinivas Akkaraju and affiliated entities
Beneficial ownership percentage (Dr. Akkaraju)9.99%Portion of PMV common stock beneficially owned by Srinivas Akkaraju
Common shares held by each Samsara fund3,620,000 sharesDirect common stock holdings of each of Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P.
Pre-Funded Warrants per Samsara fund3,400,000 sharesMaximum PMV common shares issuable upon exercise of Pre-Funded Warrants held by each Samsara fund
Common Warrants per Samsara fund7,020,000 sharesMaximum PMV common shares issuable upon exercise of Common Warrants held by each Samsara fund
Shares outstanding basis (Form 10-Q)53,458,058 sharesPMV common shares outstanding as of August 14, 2026, used in ownership percentage calculation
Shares issued in equity offering22,055,000 sharesPMV common shares issued in the public offering that closed on September 2, 2026
Beneficial Ownership Blocker threshold9.99%Maximum ownership level allowed after warrant exercise for each holder and affiliates
Key Terms
Pre-Funded Warrants, Common Warrants, Beneficial Ownership Blockers, beneficially owned, +1 more
5 terms
Pre-Funded Warrantsfinancial
"pre-funded warrants ("Pre-Funded Warrants") exercisable for up to 3,400,000 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Common Warrantsfinancial
"common warrants ("Common Warrants" and, together with the Pre-Funded Warrants"
A common warrant is a tradable instrument that gives its holder the right to buy a company’s common shares at a fixed price within a set time period, similar to a coupon that can be redeemed later to purchase stock. Investors care because exercising warrants can boost potential gains if the stock rises, but it can also dilute existing shareholders by increasing the number of shares outstanding, which can lower per-share value.
Beneficial Ownership Blockersfinancial
"Each of the Warrants contains a provision (the "Beneficial Ownership Blockers")"
beneficially ownedfinancial
"the aggregate number of shares of common stock of the Issuer beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting powerfinancial
"Shared Voting Power 3,788,734.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in PMV Pharmaceuticals (PMVP) do the Samsara entities and Srinivas Akkaraju report?
They report beneficial ownership of 7,577,467 shares of common stock, representing 9.99% of PMV’s outstanding common stock, including common shares and shares underlying Pre-Funded Warrants and Common Warrants that are exercisable within 60 days.
How many PMVP common shares and warrants are held by each of the Samsara funds?
Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P. each directly hold 3,620,000 common shares, Pre-Funded Warrants exercisable for up to 3,400,000 shares, and Common Warrants exercisable for up to 7,020,000 shares of PMV common stock.
What share count does the 9.99% ownership of PMVP by Dr. Akkaraju rely on?
The 9.99% is based on 53,458,058 shares of common stock outstanding as of August 14, 2026 plus 22,055,000 shares issued in PMV’s public equity offering that closed on September 2, 2026, and Warrants exercisable within 60 days.
What is the Beneficial Ownership Blocker affecting the PMVP warrants held by the Samsara entities?
Each Warrant includes a Beneficial Ownership Blocker that prevents exercise if, after exercise, the holder and its affiliates would own more than 9.99% of PMV’s common stock; this currently caps the reporting persons’ ownership at 7,577,467 shares.
Which reporting persons filed the Schedule 13G for PMV Pharmaceuticals (PMVP)?
The reporting persons are Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, Samsara Opportunity Fund, L.P., Samsara Opportunity Fund GP, LLC, and Srinivas Akkaraju, who together report shared voting and dispositive power over the disclosed securities.
What are the reported voting and dispositive powers over PMVP shares by the Samsara entities?
Samsara BioCapital, L.P. and Samsara BioCapital GP, LLC each report 3,788,734 shares with shared voting and dispositive power, while Samsara Opportunity Fund, L.P. and its GP each report 3,788,733 shares with shared voting and dispositive power; none report sole voting or dispositive power.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
PMV Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, $0.00001 par value per share
(Title of Class of Securities)
69353Y103
(CUSIP Number)
09/02/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
69353Y103
1
Names of Reporting Persons
Samsara BioCapital, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,788,734.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,788,734.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,788,734.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
69353Y103
1
Names of Reporting Persons
Samsara BioCapital GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,788,734.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,788,734.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,788,734.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
69353Y103
1
Names of Reporting Persons
Samsara Opportunity Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,788,733.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,788,733.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,788,733.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
69353Y103
1
Names of Reporting Persons
Samsara Opportunity Fund GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,788,733.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,788,733.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,788,733.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
69353Y103
1
Names of Reporting Persons
Srinivas Akkaraju
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
7,577,467.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
7,577,467.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,577,467.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
PMV Pharmaceuticals, Inc.
(b)
Address of issuer's principal executive offices:
400 Alexander Park Drive, Suite 301, PRINCETON, NJ, 08540.
Item 2.
(a)
Name of person filing:
The names of the persons filing this report (collectively, the "Reporting Persons") are:
Samsara BioCapital, L.P. ("Samsara LP")
Samsara BioCapital GP, LLC ("Samsara GP")
Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund")
Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP")
Srinivas Akkaraju ("Dr. Akkaraju")
The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
(b)
Address or principal business office or, if none, residence:
All of the entities were organized in Delaware; Dr. Akkaraju is a United States citizen.
(d)
Title of class of securities:
Common Stock, $0.00001 par value per share
(e)
CUSIP Number(s):
69353Y103
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
The Reporting Persons' beneficial ownership of the Issuer's securities includes: (i) 3,620,000 shares of common stock, pre-funded warrants ("Pre-Funded Warrants") exercisable for up to 3,400,000 shares of common stock and common warrants ("Common Warrants" and, together with the Pre-Funded Warrants, the "Warrants") exercisable for up to 7,020,000 shares of common stock directly held by Samsara LP and (ii) 3,620,000 shares of common stock, Pre-Funded Warrants exercisable for up to 3,400,000 shares of common stock and Common Warrants exercisable for up to 7,020,000 shares of common stock directly held by Samsara Opportunity Fund.
Each of the Warrants contains a provision (the "Beneficial Ownership Blockers") which precludes exercise of the Warrants to the extent that, following exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the common stock outstanding. By virtue of the Beneficial Ownership Blocker, each of Samsara LP and Samsara Opportunity Fund is currently prohibited from exercising the Warrants to the extent that such exercise would result in the Reporting Persons' beneficial ownership of more than 7,577,467 shares of common stock.
Samsara GP is the sole general partner of Samsara LP and Dr. Akkaraju is the managing member of Samsara GP. Each of Samsara GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara LP.
Samsara Opportunity GP is the sole general partner of Samsara Opportunity Fund and Dr. Akkaraju is the managing member of Samsara Opportunity GP. Each of Samsara Opportunity GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara Opportunity Fund.
(b)
Percent of class:
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentage of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. The percentage set forth in each row 11 is based upon the sum of (i) 53,458,058 shares of common stock outstanding as of August 14, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 14, 2026 and (ii) 22,055,000 shares of common stock issued in the Issuer's public offering of equity securities that closed on September 2, 2026, as reported in the Issuer's Current Report on Form 8-K filed with the SEC on September 2, 2026, and giving effect to Warrants, to the extent exercisable within 60 days hereof, as referenced herein.
Dr. Akkaraju beneficially owns 9.99% of the Issuer's outstanding common stock. Due to field limitations of the EDGAR filing system, the percentage listed in Row 11 of Dr. Akkaraju's cover page has been rounded down to 9.9%.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Samsara BioCapital, L.P.
Signature:
/s/ Srinivas Akkaraju
Name/Title:
By Samsara BioCapital GP, LLC, its General Partner, By Srinivas Akkaraju, Managing Member
Date:
09/15/2026
Samsara BioCapital GP, LLC
Signature:
/s/ Srinivas Akkaraju
Name/Title:
By Srinivas Akkaraju, Managing Member
Date:
09/15/2026
Samsara Opportunity Fund, L.P.
Signature:
/s/ Srinivas Akkaraju
Name/Title:
By Samsara Opportunity Fund GP, LLC, its General Partner, By Srinivas Akkaraju, Managing Member
